Nano-X Imaging

Nano-X Imaging Ltd. is engaged in the development of medical imaging systems. Its product Nanox System consists of hardware Nanox.ARC and software Nanox.CLOUD that provides image repository, radiologist matching, online and offline diagnostics review and annotation, connectivity to diagnostic assistive artificial intelligence systems, billing, and reporting. The firm operates through the following segments: Nanox.Arc, AI Solutions, and Radiology Services. The company was founded by Ran Poliakine and Hitoshi Masuya in 2011 and is headquartered in Neve Ilan, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Nano-X Imaging reports progress in regulatory clearances and strategic partnerships

Nano-X Imaging showcased progress in regulatory clearances, commercialization efforts, strategic partnerships, and operational optimization during the Q4 2022 Earnings Call.
Despite challenges in regulatory compliance, expenses management, and market competition, the company's strengths in innovation, partnerships, and financial resilience position it well for future growth.
Opportunities for Nano-X Imaging include global expansion, technological advancements, cost efficiencies, and leveraging market demand for imaging solutions.
Overall, Nano-X Imaging's performance in Q4 2022 reflects a strategic focus on growth, innovation, and market expansion in the medical imaging industry.

Nano-X Imaging reports improved Q1 performance and expands global reach

Nano-X Imaging's Q1 2023 performance showed improvement with a reported net loss of $11.8 million and revenue of $2.4 million. The company is focusing on deploying Nanox.ARC globally, strengthening manufacturing capabilities, and expanding market reach through strategic partnerships. Challenges include managing expenses and driving revenue growth to achieve profitability.

Nanox Imaging reports Q2 results, eyes U.S. market growth

Nanox Imaging's Q2 2023 performance reflects investment in growth initiatives, with a focus on market expansion and product deployment.
The company faces financial challenges, including a significant net loss and accrued expenses related to an SEC investigation, necessitating prudent financial management.
Strategic strengths in the U.S. market entry, global commercialization efforts, and strong cash position position Nanox Imaging for future growth and market success.
Opportunities lie in upcoming Investor Day, FDA clearance for Nanox.ARC, and expansion in Africa, offering avenues for revenue growth and market leadership.

Nanox Imaging reports Q3 revenue growth and strategic advancements

Nanox Imaging's Q3 2023 performance showed revenue growth and strategic advancements. While facing financial challenges and potential execution hurdles, the company's focus on expansion and partnerships positions it for future growth.

Nanox Imaging reports Q4 loss, eyes global expansion and AI

Nanox Imaging's Q4 2023 performance showed a mix of revenue growth and strategic investments in technology and market expansion.
The company's strengths lie in its progress with regulatory clearances, commercialization efforts, and success in AI applications.
Challenges include slow AI adoption, implementation hurdles, and the need to overcome barriers to data sharing and transparency.
Opportunities exist in expanding HealthCCS usage, global market presence, and addressing AI adoption challenges for revenue growth.

Nanox Imaging reports Q1 loss, eyes global expansion and AI growth

Nanox Imaging's Q1 2024 performance reflects revenue generation from AI solutions and system sales amid challenges in gross profit margins and a notable net loss.
The company's strategic strengths in partnerships, product launches, and global expansions position it well for future growth and market competitiveness.
While facing challenges in cost management and profitability, Nanox Imaging holds opportunities in expanded indications, market expansions, and AI solutions deployment.

Nano-X Imaging reports Q2 losses, eyes growth through FDA clearances

Nano-X Imaging (NNOX) showcased progress in commercial and clinical fronts but faces challenges in narrowing losses and optimizing operations.
Strategic collaborations, FDA clearances, and global deployment offer opportunities for growth and market expansion.
The focus on transformative imaging solutions and commercial infrastructure acceleration underlines NNOX's commitment to innovation and market leadership.

Nanox Imaging reports mixed Q3 results amidst growth opportunities

Nanox Imaging reported mixed financial results with revenue of $3.0 million and a gross loss of $2.8 million, while achieving record revenue from USARAD business.
The company showcased strengths in technology deployment, partnerships, and clinical trials, but faces challenges in regulatory clearances and financial performance.
Opportunities exist in market expansion, revenue growth, and operational efficiency improvements to drive future success and profitability.
With a strong focus on innovation, partnerships, and market expansion, Nanox is poised for growth but needs to address regulatory hurdles and financial performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nano-X Imaging Ltd. is engaged in the development of medical imaging systems. Its product Nanox System consists of hardware Nanox.ARC and software Nanox.CLOUD that provides image repository, radiologist matching, online and offline diagnostics review and annotation, connectivity to diagnostic assistive artificial intelligence systems, billing, and reporting. The firm operates through the following segments: Nanox.Arc, AI Solutions, and Radiology Services. The company was founded by Ran Poliakine and Hitoshi Masuya in 2011 and is headquartered in Petach Tikva, Israel.

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Nano-X business and prospects, resulting in its stock trading at inflated prices.

Notice of Lead Plaintiff Deadline for Shareholders in the Nano-X Imaging Ltd. Class Action Lawsuit

Limelight Networks

Zynga

A company's market cap is far more important than share price when looking for potential winning stocks.

Forget Penny Stocks -- 3 Better Stocks to Buy in October

New York, New York--(Newsfile Corp. - October 2, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Nano-X Imaging Ltd. (NASDAQ: NNOX), between August 21, 2020 and September 15, 2020, inclusive (the "Class Period"), of the important November 16, 2020 lead plaintiff deadline in the securities class action commenced by the firm. The lawsuit seeks to recover damages for Nano-X investors under the federal securities laws.To...

Rosen, Recognized Investor Counsel, Reminds Nano-X Imaging Ltd. Investors of Important Deadline in Securities Class Action - NNOX

Nano-X Announces Live Demonstration of Its ARC Device

This pre-revenue company was attacked by short-sellers, but it's not going down without a fight.

Why Nano-X Imaging Stock Fell Almost 15% in September

The company is fighting back against short-sellers with a planned demo of its medical imaging technology.

Why Nano-X Stock Is Crushing It Today

NEW YORK--(BUSINESS WIRE)---- $NNOX #classaction--The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Eastern District of New York on behalf of those who acquired Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ: NNOX) securities during the period from August 21, 2020 through September 15, 2020 (the “Class Period”). Investors have until November 16, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Accord

INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed Against Nano-X Imaging Ltd. and Encourages Investors to Contact the Firm Before November 16, 2020

NEVE ILAN, Israel, Oct. 01, 2020 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, is pleased to announce today that it will demonstrate its novel technology (Nanox.SOURCE) and medical imaging system (Nanox.ARC) at RSNA 2020, which is being held November 29-December 5 in Chicago.

Nanox Announces Live Demonstration of its Nanox.ARC System at Radiology Society of North America (RSNA) 2020

PHILADELPHIA, Oct. 1, 2020 /PRNewswire/ -- Kaskela Law LLC announces that a shareholder class action lawsuit has been filed against Nano-X Imaging Ltd. ("Nano-X" or the "Company") (NASDAQ: NNOX) on behalf of investors who purchased Nano-X's securities between August 21, 2020 and September...

SHAREHOLDER ALERT: Kaskela Law LLC Announces Class Action Lawsuit Against Nano-X Imaging Ltd. (NNOX) and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

San Francisco, California--(Newsfile Corp. - September 30, 2020) - Hagens Berman urges Nano-X Imaging Ltd. (NASDAQ: NNOX) investors to contact the firm now. Class Period: Aug. 21, 2020 - Sept. 15, 2020Lead Plaintiff Deadline: Nov. 16, 2020Visit: www.hbsslaw.com/investor-fraud/NNOXContact An Attorney Now: NNOX@hbsslaw.com 844-916-0895Nano-X Imaging (NNOX) Securities Class Action:The complaint alleges that throughout the Class Period, Defendants concealed that Nano-X's: (1) commercial agreements an

NNOX SECURITIES FRAUD: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Nano-X Imaging (NNOX) Investors of Securities Fraud Lawsuit and Encourages Investors with Losses to Contact the Firm, Hedge Funds Call NNOX "Theranos 2.0" and "Garbage"

After suffering two brutal short attacks, Nano-X stock has dropped 50% in a couple of weeks. Should investors flee, or is this actually a buying opportunity?

Why Are People Shorting Nano-X?

Israel-based company Nano X Imaging Ltd. (NASDAQ:NNOX) has made headlines recently with its futuristic X-ray machine design and claims that it can significantly reduce the cost of scans. It wants to achieve this by using a new type of X-ray source (called the Nanox.ARC), which will provide digital scans that can be uploaded to the internet and analyzed remotely by a network of radiologists and artificial intelligence.

Why Investors Should Think Twice Before Betting on Nano X Imaging

San Francisco, California--(Newsfile Corp. - September 24, 2020) -  Hagens Berman urges Nano-X Imaging Ltd. (NASDAQ: NNOX) investors to contact the firm now.  Class Period: Aug. 21, 2020 - Sept. 15, 2020Lead Plaintiff Deadline: Nov. 16, 2020Visit: www.hbsslaw.com/investor-fraud/NNOXContact An Attorney Now: NNOX@hbsslaw.com844-916-0895Nano-X Imaging (NNOX) Securities Class Action:The complaint alleges that throughout the Class Period, Defendants concealed that Nano-X's: (1) commercial agreements and custo

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Nano-X Imaging (NNOX) Investors of Securities Fraud Lawsuit and Encourages Investors with Losses to Contact the Firm, Hedge Funds Call NNOX "Theranos 2.0" and "Garbage"

NEW YORK, Sept. 24, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nano-X Imaging Ltd. ("Nano-X" or the "Company") (NASDAQ: NNOX) and certain of its officers. The class action, filed in United States District Court for the Eastern District...

Pomerantz Law Firm Announces the Filing of a Class Action against Nano-X Imaging Ltd. and Certain Officers -  NNOX

New York, New York--(Newsfile Corp. - September 24, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Nano-X Imaging Ltd. (NASDAQ: NNOX), between August 21, 2020 and September 15, 2020, inclusive (the "Class Period"), of the important November 16, 2020 lead plaintiff deadline in the securities class action commenced by the firm. The lawsuit seeks to recover damages for Nano-X investors under the federal securities laws.To join...

Rosen, A Trusted and Top Ranked Law Firm, Reminds Nano-X Imaging Ltd. Investors of Important Deadline in Securities Class Action - NNOX

New York, New York--(Newsfile Corp. - September 24, 2020) -  Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Nano-X Imaging Ltd. ("Nano-X" or "the Company") (NASDAQ: NNOX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Nano-X securities between August 21, 2020 and September 15, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by...

NNOX Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Nano-X Imaging Ltd. Shareholders of Class Action and Encourages Shareholders to Contact the Firm

Philadelphia, Pennsylvania--(Newsfile Corp. - September 24, 2020) - Berger Montague is investigating potential securities fraud claims against Nano-X Imaging Ltd. ("Nano-X" or the "Company") on behalf of investors who purchased Nano-X securities (NASDAQ: NNOX) between August 21, 2020 and September 15, 2020 (the "Class Period"). If you purchased Nano-X securities during the Class Period, have questions concerning your rights or interests, or would like to discuss Berger Montague's investigation, please contact attorneys Andrew Abramowitz at...

Berger Montague Investigates Alleged Securities Fraud Claims Against Nano-X Imaging Ltd. (NNOX); Lead Plaintiff Deadline is November 16, 2020

NEW YORK, Sept. 23, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Nano-X Imaging Ltd. (NASDAQ: NNOX), between August 21, 2020 and September 15, 2020, inclusive (the "Class Period"), of the important November 16, 2020 lead...

ROSEN, A TOP RANKED FIRM, Reminds Nano-X Imaging Ltd. Investors of Important November 16 Deadline in Securities Class Action First Filed by the Firm - NNOX

NEVE ILAN, Israel and TAIPEI, Taiwan, Sept.  23, 2020  (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology Company, announced today that the Company has appointed Gilad Yron to the position of Chief Business Officer. In this newly created role, Mr. Yron will play a lead role in executing the Company’s existing MSaaS agreements (medical screening as a service) while in parallel refining the Company’s commercial strategy and overseeing customer-facing activities.

Nanox Appoints Gilad Yron as Chief Business Officer

In this wide-ranging exclusive interview, Nano-X's CEO Ran Poliakine answers pressing questions about the company's technology, market opportunity, business model, and more.

Exclusive Interview: The Motley Fool Sits Down With Nano-X Imaging

San Francisco, California--(Newsfile Corp. - September 22, 2020) -  Hagens Berman urges Nano-X Imaging Ltd. (NASDAQ: NNOX) investors to contact the firm now.  Class Period: Aug. 21, 2020 - Sept. 15, 2020Lead Plaintiff Deadline: Nov. 16, 2020Visit: www.hbsslaw.com/investor-fraud/NNOXContact An Attorney Now: NNOX@hbsslaw.com844-916-0895Nano-X Imaging (NNOX) Securities Class Action:The complaint alleges that throughout the Class Period, Defendants concealed that Nano-X's: (1) commercial agreements and customers were fa

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Nano-X Imaging (NNOX) Investors to Contact Its Attorneys: Securities Fraud Case Filed, Hedge Funds Call NNOX "Theranos 2.0" and "Garbage"

New York, New York--(Newsfile Corp. - September 22, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Nano-X Imaging Ltd. ("Nano-X" or the "Company") (NASDAQ: NNOX) of the November 16, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in NANO-X stock or options

Nano-X Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Nano-X Imaging Ltd. To Contact The Firm

Why Nano-X Imaging Stock Just Crashed Another 12%

San Francisco, California--(Newsfile Corp. - September 21, 2020) - Hagens Berman urges Nano-X Imaging Ltd. (NASDAQ: NNOX) investors to contact the firm now. A securities fraud class action has been filed.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Nano-X Imaging (NNOX) Investors to Contact Its Attorneys: Securities Fraud Case Filed, Hedge Fund Calls NNOX "Theranos 2.0"

Nano-X is an innovative company that will provide low-cost medical screeners to the world, which could potentially be a market worth $50bil.

News for Nano-X Imaging Stock (NNOX)